Mount Yale Investment Advisors, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Mount Yale Investment Advisors, LLC
- $1.21 Billion
- Q2 2025
A detailed history of Mount Yale Investment Advisors, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Mount Yale Investment Advisors, LLC holds 3,481 shares of CRNX stock, worth $151,423. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,481Holding current value
$151,423% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
238Shares Held
90.3MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$403 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$278 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$271 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$253 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$243 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.34B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...